VXRT · XBRL financial data

Vaxart financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (VXRT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	—	—	—	7,379	28,700	237,258
Research and development	19,863	48,749	81,054	68,142	74,213	201,576
General and administrative	15,202	21,890	29,386	22,584	20,780	17,608
Total operating expenses	34,216	73,644	114,694	90,726	94,993	219,184
Operating income (loss)	(30,170)	(72,752)	(114,587)	(83,347)	(66,293)	18,074
Interest expense	0	0	—	—	—	—
Other income (expense)	—	—	—	(62)	31	(44)
Income tax expense (benefit)	238	107	67	261	260	476
Net income (loss)	(32,220)	(70,470)	(107,758)	(82,465)	(66,948)	16,327
Earnings per share, basic USD per share	—	(0.58)	(0.84)	(0.57)	(0.33)	0.07
Earnings per share, diluted USD per share	—	—	—	—	(0.33)	0.07
Weighted average shares, basic thousands of shares	—	121,454	127,684	144,820	202,138	230,270
Weighted average shares, diluted thousands of shares	—	—	—	—	202,138	230,346

Fiscal years (VXRT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	126,870	143,745	44,013	34,755	25,229	53,814
Short-term investments	0	22,742	49,704	4,958	26,494	9,993
Accounts receivable	334	71	20	3,008	5,761	14,564
Prepaid and other current assets	1,327	2,609	3,714	2,815	4,568	20,971
Total current assets	128,531	169,167	99,451	45,536	68,260	136,123
Property and equipment, net	1,480	6,601	15,585	11,731	8,705	5,433
Right-of-use asset	6,838	13,168	25,715	24,840	20,404	11,432
Goodwill	0	4,508	4,508	4,508	4,508	4,508
Total assets	152,582	221,168	153,847	91,830	166,389	186,079
Accounts payable	2,133	3,872	5,514	1,584	6,963	21,496
Accrued liabilities	4,799	5,064	8,084	5,634	11,378	47,879
Total current liabilities	11,763	10,783	17,921	13,724	90,878	86,754
Lease liability, non-current	5,156	11,997	19,477	17,385	14,449	6,007
Total liabilities	29,178	33,637	43,250	34,025	107,464	98,281
Accumulated deficit	(148,881)	(219,351)	(327,109)	(409,574)	(476,522)	(460,195)
Total stockholders' equity	123,404	187,531	110,597	57,805	58,925	87,798
Total liabilities and equity	152,582	221,168	153,847	91,830	166,389	186,079
Common shares outstanding (cover page) thousands of shares	117,767	125,810	135,562	173,862	227,949	240,634

Fiscal years (VXRT's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(32,220)	(70,470)	(107,758)	(82,465)	(66,948)	16,327
Stock-based compensation	4,358	8,867	13,587	14,132	11,501	8,314
Net cash from operating activities	(23,750)	(59,832)	(94,779)	(70,453)	(44,764)	7,714
Purchases of property and equipment	1,223	5,157	9,601	1,871	554	145
Net cash from investing activities	(1,220)	(49,097)	(20,415)	43,952	(21,324)	16,632
Proceeds from issuing common stock	9,175	0	17,237	—	—	—
Net cash from financing activities	138,314	125,804	17,462	15,243	56,562	4,239
Net change in cash	113,344	16,875	(97,732)	(11,258)	(9,526)	28,585

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Vaxart	50,929	27,185	2,778*	242.8M	—	Q2 FY26 10-QJun 30, 2026
Ironwood Pharmaceuticals	79,127	113,041	58,276*	165.2M	—	Q2 FY26 10-QJun 30, 2026
Achieve Life Sciences	47,958	not reported	(10,777)*	102.9M	17.4 quarters	Q2 FY26 10-QJun 30, 2026
Fennec Pharmaceuticals	41,249	17,874	50*	35.1M	—	Q2 FY26 10-QJun 30, 2026
Milestone Pharmaceuticals	169,728	559	(22,714)*	124.5M	7.5 quarters	Q2 FY26 10-QJun 30, 2026
Atossa Therapeutics	26,094	not reported	(9,644)*	10.0M	2.7 quarters	Q2 FY26 10-QJun 30, 2026
Assembly Biosciences	32,286	not reported	(15,488)*	20.4M	20.7 quarters	Q2 FY26 10-QJun 30, 2026
Cartesian Therapeutics	147,606	0	(21,082)*	30.3M	7.0 quarters	Q2 FY26 10-QJun 30, 2026
Galectin Therapeutics	13,269	not reported	(2,439)*	100.8M	5.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.